111, Inc. (NASDAQ: YI) disclosed that it has inked a strategic partnership agreement on direct supply with Xi'an Beilin Pharmaceutical Co., Ltd. (Beilin Pharmaceutical). The collaboration is a landmark event with far-reaching implications, and it is a natural result of the two firms' strategic alignment, integrated development, win-win partnership, value creation, and other factors.
As per the partnership agreement, Beilin Pharmaceutical will actively collaborate with 111 to construct a key development platform of complementary advantages, information exchange, mutual benefit, and win-win, as well as embrace more new prospects and fulfill market expectations.
Furthermore, the partnership agreement will allow the two parties to fully utilize their advantages, investigate digital marketing of Chinese patent medicines, and delve into the market's vast resources and potential. In addition, 111 and Beilin Pharmaceutical will collaborate to increase the market coverage of high-quality Chinese patent medications and improve their accessibility to benefit more consumers by leveraging the Internet's digital, intelligent, and efficient capabilities.
Moreover, 111 has long been looking for new methods to reorganize the healthcare industry value chain and better integrate demand and supply. 111's mission has been to collaborate with partners to overcome difficult obstacles, break new ground, and produce greater societal value. It is eager to collaborate with Beilin Pharmaceutical to expand the digital development path for Chinese patent medicines to achieve even greater success in the future.